Heat shock protein-based vaccines and immunotherapies

Details Heat shock protein-based vaccines and immunotherapies Heat shock protein-based vaccines and immunotherapies

2004-02-12

2008-09-02

Campbell, Bruce (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C424S278100, C424S277100, C530S300000

Reexamination Certificate

active

07420037

ABSTRACT:
Hybrid antigens comprising an antigenic domain and improved heat shock protein binding domains are described which are useful for the induction of an immune response to the antigenic domain and thus can be used to treat infectious diseases and cancers that express an antigen of the antigenic domain.

REFERENCES:
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5498538 (1996-03-01), Kay et al.
patent: 5541109 (1996-07-01), Searfoss
patent: 5679352 (1997-10-01), Chong et al.
patent: 5750119 (1998-05-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5935576 (1999-08-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5962262 (1999-10-01), Hillman et al.
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6017540 (2000-01-01), Srivastava et al.
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: 6127393 (2000-10-01), Fernandex-Pol
patent: 6258782 (2001-07-01), Barney et al.
patent: 6663868 (2003-12-01), Rothman et al.
patent: 2003/0166530 (2003-09-01), Rothman et al.
patent: 2004/0043419 (2004-03-01), Rothman et al.
patent: 2004/0071656 (2004-04-01), Weiland et al.
patent: 2005/0214312 (2005-09-01), Fletchner et al.
patent: 0 538 952 (1993-04-01), None
patent: WO 89/04871 (1989-06-01), None
patent: WO 93/17712 (1993-09-01), None
patent: WO 94/11513 (1994-05-01), None
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 96/10411 (1996-04-01), None
patent: WO 97/06685 (1997-02-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/10000 (1997-03-01), None
patent: WO 97/10001 (1997-03-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 97/26910 (1997-07-01), None
patent: WO 98/23735 (1998-06-01), None
patent: WO 98/35705 (1998-08-01), None
patent: WO 99/22761 (1999-05-01), None
patent: WO 99/42121 (1999-08-01), None
patent: WO 03/062262 (2003-07-01), None
Arnold et al., 1995, “Cross-priming of Minor Histocompatibility Antigen-specific Cytotoxic T Cells upon Immunization with the Heat Shock Protein gp96.” J. Exp. Med. 182:885-9.
Auger et al., 1996, “HLA-DR4 and HLA-DR10 motifs that carry susceptibility to rheumatoid arthritis bind 70-kD heat shock proteins.” Nature Medicine 2:306-310.
Barrios et al., 1992, “Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmete Guerin priming.” Euro. J. Immunol. 22:1365-1372.
Barrios et al., 1994, “Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD.” Clin. Exp. Immunol. 98:224-228.
Barrios et al., 1994,“Heat shock proteins as carrier molecules: in vivo helper effect mediated byEscherichia coliGroEL and DnaK proteins requires cross-linking with antigen.” Clin. Exp. Immunol. 98:229-233.
Bauer et al., 1995, “Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7.” Scand. J. Immunol. 42:317-323.
Blachere & Srivastava, 1995, “Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors.” Seminars in Cancer Biology 6:349-355.
Blachere et al., 1993,“Heat shock protein vaccines against cancer.”, J. Immunother. 14(4):352-356.
Blachere et al., 1997, “Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity.” J. Exp. Med. 186:1315-1322.
Blond-Elguindi et al., Affinity Panning of a Library of Peptides Displayed on Bacteriophages Reveals the Binding Specificity of BiP. Cell 75:717-728 (1993).
Borras-Cuesta et al., 1987, “Engineering of immunogenic peptides by co-linear synthesis of determinants recognized by B and T cells.” Eur. J. Immunol. 17:1213-1215.
Castelli et al., 2001, “Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.” Cancer Res. 61(1):222-227.
Chen et al., 2000, “Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene.” Cancer Res. 60(4):1035-1042.
Cox et al., 1988, “Orientation of epitopes influences the immunogenicity of synthetic peptide dimers.” Eur. J. Immunol. 18:2015-2019.
Czar et al., 1997, “Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus.” Biochemistry 36:7776-7785.
Davidoff et al., 1992, “Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.” Proc. Natl. Acad. Sci. USA 89:3439-3442.
Del Guidice, 1994, “Hsp70: a carrier molecule with built-in adjuvanticity.” Experientia 50:1061-1066.
DeNagel & Pierce et al., 1993, “Heat shock proteins in immune responses.” Critical Reviews In Immunology 13:71:81.
Dillman et al., 1995, “Heat Shock Proteins and Ischemic Injury.” J. Cell. Biochem., Suppl. 19B, p. 190.
Edgington, 1995, “Therapeutic applications of heat shock proteins.” Biotechnol. 13:1442-1444.
Fedoseyeva et al., 2001, “CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice.” J. Immunol. 164(11):5641-5651.
Feldweg & Srivastava, 1995, “Molecular heterogeneity of tumor rejection antigen/heat shock protein GP96.” Int. J. Cancer 63:310-314.
Flajnik et al., 1991, “Which came first, MHC Class 1 or Class I1?” Immunogenetics 33:295-300.
Flynn et al., 1989, “Peptide-dependent stimulation of the ATPase activity of the molecular chaperone BiP is the result of conversion of oligomers to active monomers.” Science 245:385-390.
Francis et al., 1987, “Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants.”Nature 330:168-170.
Galigniana et al., 1998, “Heat shock protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton.” Mol. Endo. 12:1903-1913.
Gething, et al., 1995, “Binding Sites for Hsp70 Molecular Chaperones in Natural Proteins.” Cold Spring Harb. Symp. Quant. Biol. 60:417-28.
Giboa, 1996, “Immunotherapy of cancer with genetically modified tumor vaccines.” Seminars in Oncology 23:101-107.
Gragerov et al., 1994, “Different peptide binding specificities of hsp70 family members.” J. Mol. Biol. 235:133-135.
Gragerov et al., 1994, “Specificity of DnaK-peptide binding.” J. Mol. Biol. 235:848-854.
Greene et al., 1995, “Effect of nucleotide on the binding of peptides to 70-kDa heat shock protein.” J. Biol. Chem. 270(7):2967-2978.
Heike et al., 1996, “Heat shock protein-peptide complexes for use in vaccines.” J. Leukoc. Biol. 60(2):153-158.
Heikema et al., 1997, “Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides.” Immunol. Lett. 57(1-3):69-74.
Hinds et al., 1987, “Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines.” Mol Cell Biol. 7(8):2863-2869.
Hohfeld et al., 1995, “Hip, a novel cochaperone involved in the eukaryotic Hsc70/Hsp40 reaction cycle.” Cell 83:589-598.
Huang et al., 2000, “In Vivo Cytotoxic T Lymphocytes Elicitation by Mycobacterial Heat Shock Protein 70 Fusion Proteins Maps to a Discrete Domain and Is CD4.sup.30 T Cell Independent.” J. Exp. Med. 191:403-408.
Jaattela, 1995, “Over-expression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells.” Int. J. Cancer, 60 (5), pp. 689-693.
Jakob et al., 1996, “Assessment of the ATP binding properties of Hsp90.” J. Biol.

Affiliated with

Also associated with

Rating

Heat shock protein-based vaccines and immunotherapies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heat shock protein-based vaccines and immunotherapies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heat shock protein-based vaccines and immunotherapies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3970719